Neogen Stock Gets Stronger EPS Estimate from Zacks Research

Key Points

• Zacks Research raised Neogen’s Q3 2027 EPS forecast to $0.07 from $0.06, while projecting $0.27 in FY2027 earnings and $0.31 in FY2028.
• Neogen’s latest quarter beat expectations, reporting $0.08 EPS versus $0.05 estimated and revenue of $222.8 million versus $208.18 million; revenue increased 6.5% year over year.
• Shares opened at $12.12 after falling 2.8%, while analyst sentiment remained mixed with a consensus “Hold” rating and an average price target of $12.67. Institutional investors own 96.73% of the stock.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Stock analysts at Zacks Research upped their Q3 2027 earnings per share (EPS) estimates for Neogen in a report released on Tuesday, October 27th. Zacks Research analyst Team now expects that the company will post earnings of $0.07 per share for the quarter, up from their prior forecast of $0.06. The consensus estimate for Neogen's current full-year earnings is $0.27 per share. Zacks Research also issued estimates for Neogen's Q4 2027 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS, FY2028 earnings at $0.31 EPS and Q1 2029 earnings at $0.07 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its quarterly earnings data on Tuesday, October 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.03. The business had revenue of $222.80 million for the quarter, compared to the consensus estimate of $208.18 million. Neogen had a positive return on equity of 3.29% and a negative net margin of 6.35%. The business's revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.04 earnings per share.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Neogen from a "strong-buy" rating to a "buy" rating in a research note on Sunday, October 11th. Guggenheim reiterated a "buy" rating and set a $14.00 price target (up from $12.00) on shares of Neogen in a report on Wednesday, September 30th. Weiss Ratings raised shares of Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Finally, Piper Sandler raised shares of Neogen from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $13.00 to $14.00 in a research note on Wednesday, August 26th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $12.67.

Neogen Trading Down 2.8%

Shares of NEOG stock opened at $12.12 on Thursday. The firm has a 50-day moving average price of $12.22 and a 200 day moving average price of $10.39. Neogen has a twelve month low of $5.37 and a twelve month high of $14.26. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -48.48, a PEG ratio of 4.46 and a beta of 1.79. The company has a current ratio of 3.90, a quick ratio of 2.92 and a debt-to-equity ratio of 0.37.

Institutional Trading of Neogen

A number of hedge funds have recently added to or reduced their stakes in NEOG. BlackRock Inc. purchased a new position in shares of Neogen in the 2nd quarter worth about $300,545,000. Bamco Inc. NY acquired a new position in Neogen during the 2nd quarter worth approximately $45,094,000. Cibc World Market Inc. purchased a new position in shares of Neogen in the second quarter valued at $31,469,000. Bank of America Corp DE acquired a new stake in shares of Neogen during the second quarter valued at about $28,280,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Neogen by 23.4% during the first quarter. Dimensional Fund Advisors LP now owns 9,132,021 shares of the company's stock worth $84,831,000 after acquiring an additional 1,733,767 shares during the last quarter. 96.73% of the stock is owned by institutional investors and hedge funds.

About Neogen

Neogen Corporation develops and markets products and services designed to help protect the food supply and support animal health. Its food safety offerings include diagnostic tests and laboratory products used to detect pathogens, allergens, mycotoxins, genetically modified organisms, veterinary drug residues, and other contaminants in food and agricultural environments.

The company also provides sanitation and hygiene products, environmental monitoring solutions, and software and data-management tools that help food processors, retailers, laboratories, and other organizations manage food safety programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.